Table of Content

1. Executive Summary
• Introduction
2. Pipeline Analysis
• Assessment by Phase
o Phase I Clinical Trials
o Phase II Clinical Trials
o Phase III Clinical Trials
• Assessment by Mechanism of Action
o Prophylactic Vaccines
o Therapeutic Vaccines
• Assessment by Route of Administration
o Intramuscular
o Intravenous
o Intradermal
• Assessment by Modality
o Conventional mRNA Vaccines
o Self-amplifying mRNA (saRNA) Vaccines
3. List of Key Companies Involved
• Moderna, Inc.*
o Drug Profile
• BioNTech SE
• Sanofi
• GSK plc
• AstraZeneca
• Merck & Co., Inc.
• F. Hoffmann-La Roche Ltd
• RinuaGene
4. Regulatory Designations
• Orphan Drug Designation
• Fastrack Designation
• Breakthrough Therapy Designation
• Priority Review
• PRIME Designation
• RMAT Designation
• ATMP Designation
5. Clinical Data Readouts
• Trial Initiation
• Trial Completion
• Safety/Efficacy- Data Readouts
• Discontinued Products
6. Estimated Approvals
7. Merger and Acquisitions
8. Future Perspectives and Conclusion